GlassScriptPhysician profile
Ambareen Salam
NPI 1053350488
$2,914.52
in general payments reported to CMS, 2019-2025
34 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $240 · 2021: $35.17 · 2022: $82.30 · 2023: $16.88 · 2024: $412 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $677.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $416.59 | 2019-2025 | Breztri |
| Lilly USA, LLC | $315.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $198.29 | 2019-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $171.71 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $171.05 | 2019-2025 | |
| Pfizer INC. | $70.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $60.11 | 2019-2020 | |
| Eisai INC. | $59.04 | 2019-2024 | |
| Cleerly, INC. | $58.61 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Abbvie INC. | $56.21 | 2019-2025 | Vraylar |
| Apollo Endosurgery US INC | $55.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.26 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.57 | 2024-2025 | Xifaxan, Trulance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.75 | 2019-2022 | |
| Abiomed | $40.01 | 2024 | Impella |
| Exact Sciences Corporation | $38.64 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $37.56 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.13 | 2019-2025 | Jascayd |
| Ge Healthcare | $32.93 | 2019 | |
| Currax Pharmaceuticals LLC | $30.18 | 2019-2024 | Contrave |
| Abbott Laboratories | $24.12 | 2025 | Proclaim |
| Biosense Webster, INC. | $23.45 | 2024 | Carto 3 |
| Dexcom, INC. | $23.32 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $17.79 | 2024 | Gemtesa |
| Astellas Pharma US INC | $17.15 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.02 | 2020 | |
| Optos, INC. | $15.03 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.30 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $14.18 | 2019 | |
| Optinose US, INC. | $13.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.14 | 2019 | |
| Bardy Diagnostics, INC. | $1.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambareen Salam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.